NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Major Shareholder Sells $185,915.52 in Stock

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) major shareholder Corp Symetryx sold 129,108 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $1.44, for a total transaction of $185,915.52. Following the completion of the sale, the insider now directly owns 153,337 shares in the company, valued at $220,805.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Corp Symetryx also recently made the following trade(s):

• On Monday, September 11th, Corp Symetryx sold 3,376 shares of NeuBase Therapeutics stock. The stock was sold at an average price of $1.44, for a total value of $4,861.44.
• On Thursday, September 7th, Corp Symetryx sold 74,852 shares of NeuBase Therapeutics stock. The stock was sold at an average price of $1.80, for a total value of $134,733.60.
• On Friday, September 1st, Corp Symetryx bought 61,076 shares of NeuBase Therapeutics stock. The shares were purchased at an average cost of $0.98 per share, for a total transaction of $59,854.48.

NeuBase Therapeutics Stock Down 7.7 %

Shares of NBSE traded down $0.10 during trading on Monday, reaching $1.20. The company’s stock had a trading volume of 627,749 shares, compared to its average volume of 859,805. NeuBase Therapeutics, Inc. has a twelve month low of $0.61 and a twelve month high of $10.79. The company has a market cap of $2.83 million, a price-to-earnings ratio of -0.10 and a beta of 0.85. The company has a fifty day moving average of $1.23 and a two-hundred day moving average of $2.61.

NeuBase Therapeutics (NASDAQ:NBSE) last posted its quarterly earnings results on Monday, August 14th. The company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.54. As a group, equities analysts forecast that NeuBase Therapeutics, Inc. will post -7.29 EPS for the current fiscal year.

Institutional Trading of NeuBase Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Manhattan Co. bought a new stake in shares of NeuBase Therapeutics in the 1st quarter worth $26,000. Renaissance Technologies LLC grew its position in NeuBase Therapeutics by 20.2% in the third quarter. Renaissance Technologies LLC now owns 287,386 shares of the company’s stock worth $114,000 after buying an additional 48,255 shares during the last quarter. State Street Corp increased its holdings in shares of NeuBase Therapeutics by 18.4% in the first quarter. State Street Corp now owns 68,687 shares of the company’s stock valued at $129,000 after buying an additional 10,674 shares in the last quarter. Royal Bank of Canada lifted its position in shares of NeuBase Therapeutics by 64.3% during the 1st quarter. Royal Bank of Canada now owns 114,473 shares of the company’s stock valued at $215,000 after acquiring an additional 44,791 shares during the last quarter. Finally, Worth Venture Partners LLC boosted its stake in shares of NeuBase Therapeutics by 11.9% during the 1st quarter. Worth Venture Partners LLC now owns 256,553 shares of the company’s stock worth $482,000 after acquiring an additional 27,300 shares in the last quarter. 24.52% of the stock is currently owned by institutional investors and hedge funds.

NeuBase Therapeutics Company Profile

NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.